Cyclopenta[C]Pyrrole-2(1H)-Carboxylic Acid, Hexahydro-5-Oxo-, 1,1-Dimethylethyl Ester

Pilot-plant campaigns for the production of macrocyclic NS3/4A protease inhibitors—most notably grazoprevir (MK-5172) and closely related decahydrocyclopenta[c]pyrrole-based assets—have demonstrated that the enantiomerically pure 1,1-dimethylethyl hexahydro-5-oxocyclopenta[c]pyrrole-2(1H)-carboxylate intermediate is critical for establishing the (4R,6S,7R) stereochemical configuration of the bicyclic core. In the amide-coupling step that joins the Boc-protected pyrrolidine to the quinoxaline-caprolactam acid fragment, the intermediate is typically charged at 1.05–1.15 molar equivalents relative to the acid component, using HATU (1.2 eq) and N,N-diisopropylethylamine (3.0 eq) in anhydrous N,N-dimethylformamide at −10 °C to 0 °C. The slight excess compensates for the reversible N-acylurea formation that consumes the activated ester, a side reaction documented in process development reports under ICH Q7 Section 7.3 starting-material characterisation protocols. Downstream, the Boc group is cleaved with trifluoroacetic acid/dichloromethane (1:3 v/v) containing 2.5% triisopropylsilane as a cation scavenger; the solution is agitated at 20 ± 2 °C for 45–60 minutes before concentration under reduced pressure (≤ 40 °C jacket temperature) in a Hastelloy C-22 reactor. This order of operations is necessary because deviation above 10 °C during acidolysis increases the diastereomeric impurity originating from epimerisation at the bridgehead carbon to > 3.0 area% by HPLC (monitored per USP <621>), rendering subsequent crystallisation ineffective. Final polishing of the advanced intermediate employs a ternary solvent system (ethyl acetate/n-heptane/methanol, 6:3:1) with seeding at 45 °C and linear cooling to −5 °C, delivering a crystalline free amine with chemical purity ≥ 99.5% and enantiomeric excess ≥ 99.7%. The entire campaign operates under FDA 21 CFR Part 211 with residual solvent limits aligned to USP <467> Class 2 thresholds for dichloromethane (NMT 600 ppm) and DMF (NMT 880 ppm). The terminal active pharmaceutical ingredient produced via this route is grazoprevir anhydrous (approved under NDA 208261), and the intermediate’s batch records must document moisture ingress (< 0.1% w/w by Karl Fischer) because of the ketone group’s susceptibility to hemiaminal adduct formation with water, which would shift the downstream macrocyclisation yield by 8–12 percentage points.

How Does the Hexahydro-5-oxo Substituent Influence Boc Deprotection Kinetics in Flow Chemistry?

Process intensification studies transferred the Boc-deprotection step to a continuous-flow platform to suppress the thermally labile hexahydro-5-oxo ring’s tendency toward retro-aldol fragmentation under batch conditions. The intermediate, dissolved in anhydrous dichloromethane at 0.5 M, is fed via a syringe pump into a Corning Advanced-Flow G1 glass module where it contacts a reagent stream of trifluoroacetic acid (4.0 equivalents, neat) pre-cooled to 5 °C. The combined stream passes through a residence-time channel with a hydraulic diameter of 0.76 mm, held at 15–18 °C by a jacket-connected thermoelectric controller, with a residence time of 18–22 seconds tuned by a back-pressure regulator set to 6.2 bar. Under these conditions the Boc cleavage proceeds to completion while the α-proton abstraction that triggers ketone epimerisation is kinetically outpaced; offline HPLC analysis (Agilent Poroshell 120 EC-C18, 2.7 µm, 4.6 × 50 mm, acetonitrile/0.1% phosphoric acid gradient) records the 5-oxo epimer at ≤ 0.28 area%, compared with 2.7–4.1 area% in a jacketed batch vessel with identical stoichiometry. Compliance with EU GMP Annex 11 for computerised systems is maintained by logging all pump rates, pressures, and temperatures in a process information management system validated under 21 CFR Part 11. The real-time PAT integration, employing a FlowIR™ in-line probe to track the carbonyl shift at 1715 cm⁻¹, further aligns with FDA Guidance for Industry—PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. The downstream workup involves continuous extraction with aqueous 10% potassium bicarbonate in a Zaiput membrane separator followed by in-line concentration in a wiped-film evaporator, directly furnishing the decahydrocyclopenta[c]pyrrole amine that is telescoped into the macrocyclisation step. The final drug substance remains a macrocyclic NS3/4A inhibitor such as grazoprevir, where the continuous deprotection sequence has reduced the specific energy consumption by 38% and eliminated the need for a dedicated clean-room chromatography suite, while keeping the overall yield above 92%.

Peptidomimetic Scaffolds for Coronavirus Protease Inhibitor Programmes

Structure-based drug design targeting the SARS-CoV-2 main protease (Mpro, 3CLpro) has identified the hexahydro-5-oxocyclopenta[c]pyrrole-2-carboxylate system as a rigid P2 proline isostere capable of orienting the P1′ hydrophobic pocket interaction while resisting oxidative metabolism at the pyrrolidine ring. During solid-phase peptide synthesis (SPPS) of reversible covalent inhibitors, the Boc-protected scaffold is loaded onto 2-chlorotrityl chloride resin (1.5 mmol/g substitution) at 3.0 equivalents relative to resin loading capacity, using HATU (2.9 eq) and DIEA (6.0 eq) in dichloromethane/DMF (1:1) for 120 minutes at ambient temperature. The quality management system for these early-phase intermediates typically conforms to ISO 9001:2015 with phase-appropriate GMP principles outlined in ICH Q11 Section 3.2 for starting material definition. Following chain elongation via Fmoc chemistry, the final cleavage and side-chain deprotection employ a cocktail of TFA/thioanisole/1,2-ethanedithiol/anisole (90:5:3:2, v/v) for 120 minutes, liberating the free amino-ketone moiety. A critical processing restriction exists: the ketone function of the cyclopenta[c]pyrrole ring undergoes rapid intramolecular aldol condensation when exposed to piperidine (20% in DMF) above pH 10.5, generating a spirocyclic byproduct that cannot be resolved by flash chromatography. Consequently, Fmoc deprotection steps must substitute piperidine with 2% DBU/2% Oxyma Pure in DMF, adding approximately 45 minutes per cycle but preserving the bicyclic scaffold integrity. The terminal products are often C-terminal aldehyde, ketoamide, or nitrile inhibitors with molecular weights between 450 and 700 Da, showing Mpro IC50 values in the low-nanomolar range when co-crystallised with the enzyme under P21 symmetry conditions. Reference standards for these molecules are analysed per ICH Q2(R1) validation parameters, and genotoxic impurity assessments follow ICH M7(R1) for the hydrazine-derived fragments occasionally present at trace level.

Certain enantioselective organocatalytic transformations exploit the chiral bicyclic pyrrolidine framework generated after removal of the tert-butyl carbamate group. In enamine-mediated asymmetric α-hydroxylation of aldehydes, the deprotected hexahydro-5-oxo amino acid (liberated via HCl/dioxane 4 M, 2 h, 25 °C followed by neutralisation with saturated NaHCO₃) is used in situ at a loading of 10 mol% with p-nitrobenzoic acid (20 mol%) as a co-catalyst. The process is executed in tetrahydrofuran at −20 °C, employing 2.0 equivalents of aqueous hydrogen peroxide (35%) as the oxidant, and the desired α-hydroxy aldehyde is isolated by flash chromatography after 48 hours with enantiomeric excess typically 92–95% (determined by chiral GC on a γ-TA column). Regulatory oversight for such fine-chemical manufacturing in the EU/EEA relies on REACH Regulation (EC) No 1907/2006, where this tert-butyl ester may be registered as a phase-in substance at the 1–10 tonnes/annum band. The operational boundary is set by the catalyst’s sensitivity to trace metals: the deprotected amino acid must be extracted with ethylenediaminetetraacetic acid disodium salt (0.1 M) to reduce residual iron below 5 ppm, otherwise oxidative degradation of the THF solvent generates acidic peroxides that racemise the product to ee < 80%. The ultimate commercial materials are chiral β-hydroxy-N-protected amino alcohols or α-hydroxy esters, serving as building blocks for antithrombotic agents bearing a phenethylamine pharmacophore.

When Residual Palladium Content Must Fall Below 10 ppm in Late-Stage Coupling Reactions

Installation of the hexahydro-5-oxocyclopenta[c]pyrrole-2-carboxylate scaffold into macrocyclic inhibitors frequently precedes a palladium-catalysed Suzuki–Miyaura cross-coupling that appends a heterobiaryl arm to the quinoxaline or caprolactam ring. Because the subsequent Boc-deprotection and macrocyclisation steps are highly sensitive to catalyst carry-over, the intermediate’s palladium level must be controlled to < 10 ppm as measured by ICP-MS (Agilent 7900, m/z 105 and 108) in accordance with ICH Q3D Guideline for Elemental Impurities, where palladium is classified as a Class 2B elemental impurity with an oral permitted daily exposure of 100 µg/day. The coupling itself proceeds with Pd(PPh₃)₄ (0.5 mol%) and potassium carbonate (3.0 equivalents) in a degassed toluene/ethanol/water (5:2:1) mixture at 75 °C for 6–8 hours, initially generating a crude solution containing 120–180 ppm Pd. Downstream metal scavenging employs a tandem treatment: first, addition of trimercaptotriazine-functionalised silica gel (5% w/w) and stirring at 55 °C for 4 hours; second, a liquid–liquid wash with 5% aqueous L-cysteine hydrochloride monohydrate at pH 7.5. The organic phase is then passed through a 0.5 µm polypropylene depth filter before concentration and crystallisation from 2-propanol/water (3:2). This protocol consistently achieves residual palladium below 5 ppm in the isolated solid, verified by a validated USP <233> sample preparation procedure. The manufacturing suite operates under ISO 8 (Class 100,000) air-handling conditions with dedicated stainless-steel equipment passivated by 10% nitric acid to prevent cross-contamination. The final products incorporating the palladium–cleansed intermediate are potent NS3/4A inhibitors that contain an aryl-heteroaryl biaryl motif—exemplified by grazoprevir—with registrational stability data generated per ICH Q1A(R2). If the 10 ppm palladium limit is breached, observable consequences include a 15–25% drop in macrocyclisation conversion and darkening of the final API colour to ≥BY6 on the European Pharmacopoeia colour scale, triggering visual inspection failure under EP 2.2.2.